Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
Nat Metab ; 2(10): 1034-1045, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-32839596

RESUMEN

Benign hepatosteatosis, affected by lipid uptake, de novo lipogenesis and fatty acid (FA) oxidation, progresses to non-alcoholic steatohepatitis (NASH) on stress and inflammation. A key macronutrient proposed to increase hepatosteatosis and NASH risk is fructose. Excessive intake of fructose causes intestinal-barrier deterioration and endotoxaemia. However, how fructose triggers these alterations and their roles in hepatosteatosis and NASH pathogenesis remain unknown. Here we show, using mice, that microbiota-derived Toll-like receptor (TLR) agonists promote hepatosteatosis without affecting fructose-1-phosphate (F1P) and cytosolic acetyl-CoA. Activation of mucosal-regenerative gp130 signalling, administration of the YAP-induced matricellular protein CCN1 or expression of the antimicrobial peptide Reg3b (beta) peptide counteract fructose-induced barrier deterioration, which depends on endoplasmic-reticulum stress and subsequent endotoxaemia. Endotoxin engages TLR4 to trigger TNF production by liver macrophages, thereby inducing lipogenic enzymes that convert F1P and acetyl-CoA to FA in both mouse and human hepatocytes.


Asunto(s)
Fructosa/farmacología , Inflamación/metabolismo , Lipogénesis/efectos de los fármacos , Acetilcoenzima A/farmacología , Animales , Endotoxemia/sangre , Femenino , Fructosafosfatos/farmacología , Microbioma Gastrointestinal , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Humanos , Intestinos/efectos de los fármacos , Lipidómica , Macrófagos/metabolismo , Ratones , Ratones Endogámicos C57BL , Enfermedad del Hígado Graso no Alcohólico/metabolismo , Regeneración/efectos de los fármacos , Receptores Toll-Like/agonistas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA